Shares of Harrow Health HROW were flat after the company reported Q2 results.
Quarterly Results
Earnings per share decreased 1000.00% year over year to ($0.11), which missed the estimate of ($0.03).
Revenue of $18,134,000 up by 124.99% from the same period last year, which beat the estimate of $15,650,000.
Outlook
Earnings guidance hasn't been issued by the company for now.
Revenue guidance hasn't been issued by the company for now.
How To Listen To The Conference Call
Date: Aug 10, 2021
Time: 04:45 PM
ET Webcast URL: https://services.choruscall.com/mediaframe/webcast.html?webcastid=I9xEp7jC
Price Action
52-week high: $11.24
Company's 52-week low was at $4.65
Price action over last quarter: down 0.66%
Company Description
Harrow Health Inc is an ophthalmology-focused pharmaceutical company. The company is specialized in the development, production, and sale of medications that offer competitive advantages and serve unmet needs in the marketplace. Its cornerstone of ophthalmology program consists of proprietary Dropless Therapy injectable and LessDrops topical formulations that are designed to address patient compliance issues and provide other compelling medical and economic benefits.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
